CHAPTER 1 INTRODUCTION

1.1 Report description
1.2 Key benefits
1.3 Key market segments
1.4 Research methodology

1.4.1 Secondary research
1.4.2 Primary research
1.4.3 Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

2.1 CXO perspective

CHAPTER 3 MARKET OVERVIEW

3.1 Market definition and scope
3.2 Biomarker diagnosis vs. conventional diagnosis
3.3 Key findings

3.3.1 Drivers

3.3.1.1 Rise in incidence and prevalence of various cancer types
3.3.1.2 Growth in importance of biological and targeted drug therapies
3.3.1.3 Expiration of key patents and biosimilars impact
3.3.1.4 Increase in acquisitions and collaborations
3.3.1.5 Technological advancements
3.3.1.6 Accuracy and reliability
3.3.1.7 Rise in investment from government, public, and private sectors
3.3.1.8 Increase in clinical trials
3.3.1.9 Growth in popularity of personalized medicine and companion diagnostics

3.3.2 Restraints

3.3.2.1 High cost of drug development and threat of failure
3.3.2.2 Unregulated government regulation and reimbursement policies
3.3.2.3 Adverse effects of cancer drug therapy

3.3.3 Opportunities

3.3.3.1 Advancement of cancer drugs research
3.3.3.2 Increased focus towards advanced treatment protocols
3.3.3.3 Significant unmet need in cancer diagnosis
3.3.3.4 Increased awareness to reduce healthcare costs
3.3.3.5 Opportunities in emerging economies

3.3.4 Top investment pockets
3.3.5 Top winning strategies

3.4 Porters five forces analysis

3.4.1 High bargaining power of suppliers
3.4.2 Low bargaining power of buyers
3.4.3 High threat from substitutes
3.4.4 Low threat of new entrants
3.4.5 High intensity of competitive rivalry

3.5 Top player positioning, 2015
3.6 Patent analysis

3.6.1 U.S. patent analysis by market participant
3.6.2 Europe patent analysis by market participant
3.6.3 China patent analysis by market participant
3.6.4 Canada patent analysis by market participant
3.6.5 Japan patent analysis by market participant
3.6.6 Other countries patent analysis by market participant

3.7 Clinical trials

CHAPTER 4 CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2014-2022

4.1 Overview

4.1.1 Market size and forecast

4.1 Omic technologies

4.1.1 Key market trends
4.1.2 Key growth factors and opportunities
4.1.3 Market size and forecast
4.1.4 Genomics

4.1.4.1 Market size and forecast
4.1.4.2 Next-generation sequencing (NGS)
4.1.4.3 Microarray
4.1.4.4 Polymerase chain reaction (PCR)

4.1.5 Proteomics

4.1.5.1 Market size and forecast
4.1.5.2 Mass spectrometry
4.1.5.3D gel electrophoresis
4.1.5.4 Protein microarray technology
4.1.5.5 Antibody array technology
4.1.5.6 Peptide array technology

4.1.6 Other omic technologies

4.1.6.1 Market size and forecast
4.1.6.2 Metabolomics
4.1.6.3 Glycomics

4.2 Imaging technologies

4.2.1 Key market trends
4.2.2 Key growth factors and opportunities
4.2.3 Market size and forecast
4.2.4 Magnetic resonance imaging
4.2.5 Positron emission tomography
4.2.6 Computed tomography
4.2.7 Mammography
4.2.8 Ultrasound

4.3 Immunoassays

4.3.1 Key market trends
4.3.2 Key growth factors and opportunities
4.3.3 Market size and forecast
4.3.4 Immunohistochemistry tests
4.3.5 Enzyme-linked immunosorbent assay
4.3.6 Flow cytometry

4.4 Cytogenetics-based tests

4.4.1 Key market trends
4.4.2 Key growth factors and opportunities
4.4.3 Market size and forecast
4.4.4 In situ hybridization
4.4.5 Others (karyotyping, amplichip, and in vitro diagnostic multivariate index assays [IVDMIA])

CHAPTER 5 GLOBAL CANCER BIOMARKERS MARKET, BY BIOMOLECULE (2014-2022)

5.1 Overview

5.1.1 Market size and forecast

5.2 Genetic biomarkers

5.2.1 Market size and forecast

5.3 Protein biomarkers

5.3.1 Market size and forecast

5.4 Glyco-biomarkers

5.4.1 Market size and forecast

CHAPTER 6 CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2014-2022

6.1 Overview

6.1.1 Market size and forecast

6.2 Lung cancer

6.2.1 Market size and forecast

6.3 Breast cancer

6.3.1 Market size and forecast

6.4 Colorectal cancer

6.4.1 Market size and forecast

6.5 Prostate cancer

6.5.1 Market size and forecast

6.1 Stomach cancer

6.1.1 Market size and forecast

6.2 Others

6.2.1 Market size and forecast

CHAPTER 7 CANCER BIOMARKERS MARKET, BY APPLICATION, 2014-2022

7.1 Overview

7.1.1 Market size and forecast

7.2 Diagnostics

7.2.1 Market size and forecast

7.3 Drug discovery and development

7.3.1 Market size and forecast

7.4 Prognostics

7.4.1 Market size and forecast

7.5 Risk assessment

7.5.1 Market size and forecast

7.6 Others (personalized medicine, surrogate endpoints, recurrence, and therapeutics)

7.6.1 Market size and forecast

CHAPTER 8 CANCER BIOMARKERS MARKET BY GEOGRAPHY, 2014-2022

8.1 Overview

8.1.1 Market size and forecast

8.2 North America

8.2.1 Key market trends
8.2.2 Growth factors and opportunities
8.2.3 Market size and forecast

8.2.3.1 U.S.: market size and forecast
8.2.3.2 Canada: market size and forecast
8.2.3.3 Mexico: market size and forecast

8.3 Europe

8.3.1 Key market trends
8.3.2 Growth factors and opportunities
8.3.3 Market size and forecast

8.3.3.1 Germany: market size and forecast
8.3.3.2 UK: market size and forecast
8.3.3.3 France: market size and forecast
8.3.3.4 Italy: market size and forecast
8.3.3.5 Russia: market size and forecast
8.3.3.6 Rest of Europe: market size and forecast

8.4 Asia-Pacific

8.4.1 Key market trends
8.4.2 Key growth factors and opportunities
8.4.3 Market size and forecast

8.4.3.1 Japan: market size and forecast
8.4.3.2 China: market size and forecast
8.4.3.3 India: market size and forecast
8.4.3.4 Australia: market size and forecast
8.4.3.5 Rest of Asia-Pacific: market size and forecast

8.5 LAMEA (Latin America, Middle East, and Africa)

8.5.1 Key market trends
8.5.2 Key growth factors and opportunities

8.5.2.1 Brazil: market size and forecast
8.5.2.2 Saudi Arabia: market size and forecast
8.5.2.3 UAE: market size and forecast
8.5.2.4 Rest of LAMEA: market size and forecast

CHAPTER 9 COMPANY PROFILES

9.1 F. Hoffmann-La Roche Ltd.

9.1.1 Company overview
9.1.2 Business performance
9.1.3 Key strategies and developments

9.2 Abbott Laboratories

9.2.1 Company overview
9.2.2 Company Snapshot
9.2.3 Operating business segments
9.2.4 Business performance
9.2.5 Key strategies & developments

9.3 GlaxoSmithKline plc

9.3.1 Company overview
9.3.2 Operating business segments
9.3.3 Business performance
9.3.4 Key strategies and developments

9.4 Novartis AG

9.4.1 Company overview
9.4.2 Operating business segments
9.4.3 Business performance
9.4.4 Key strategies and developments

9.5 Merck & Co., Inc.

9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Business performance
9.5.5 Key strategies and developments

9.6 Bristol-Myers Squibb

9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Business performance
9.6.4 Key strategies and developments

9.7 Eli Lilly and Company

9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Business performance
9.7.5 Key strategies and developments

9.8 Pfizer, Inc.

9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Business performance
9.8.5 Key strategies and developments

9.9 Qiagen N.V.

9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Key strategy move and development

9.10 Genomic Health, Inc.

9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Business performance
9.10.4 Key strategies and developments